Gyre Therapeutics Inc. (GYRE)
$9.64 -$0.02 (-0.15%) 4:38 PM 12/13/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$987.81M -
Day's Range
$9.68 - $10.22 -
Volume
150,254 -
52 Week Low / High
$8.26 - $30.40 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
Company News
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference — Oct 1st, 2024
Gyre Therapeutics, Inc. SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying,...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference — Oct 1st, 2024
Gyre Therapeutics, Inc. SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying,...
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference — Oct 1st, 2024
Gyre Therapeutics, Inc. SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying,...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference — Oct 1st, 2024
Gyre Therapeutics, Inc. SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying,...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference — Oct 1st, 2024
Gyre Therapeutics, Inc. SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying,...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference — Oct 1st, 2024
Gyre Therapeutics, Inc. SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying,...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference — Oct 1st, 2024
Gyre Therapeutics, Inc. SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying,...
-
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt — Oct 4th, 2024
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more power to influence management and governance-related decisions The largest shareholder of the company is GNI Group Ltd. with a 69% stake Ownership research, combined with ...
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference — Oct 1st, 2024
Gyre Therapeutics, Inc. SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying,...
Portfolio
Comprised of 1 portfolios